Weight Management Support: Experience potential weight loss benefits as part of your diabetes treatment plan, promoting a healthier lifestyle
Covariates Baseline covariates included age, sex, race, ethnicity, geographic region, index year, T2D history, payer type, prescribers specialty, Charlson Comorbidity Index (CCI) [24, 25], diabetes complication severity index (DCSI) [26, 27], body mass index (BMI), and number of all distinct prescription drugs
A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains
Key results: On-treatment (no interruptions): Semaglutide (Wegovy): 57% lower risk of heart attack, stroke, or death Tirzepatide: Reference comparator Including treatment gaps: Semaglutide: 29% lower risk of major adverse cardiovascular events Tirzepatide: Higher event rates in this real-world analysis Why this matters: These data suggest semaglutide may have greater cardiovascular benefit than tirzepatidea provocative finding given both are highly effective for weight loss